Entera Bio’s (ENTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a report issued on Friday morning, Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

Entera Bio Stock Performance

NASDAQ ENTX opened at $1.90 on Friday. The stock’s fifty day moving average is $1.77 and its two-hundred day moving average is $1.95. The firm has a market capitalization of $67.99 million, a P/E ratio of -6.79 and a beta of 1.57. Entera Bio has a fifty-two week low of $0.52 and a fifty-two week high of $3.35.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $0.06 million for the quarter. As a group, sell-side analysts forecast that Entera Bio will post -0.23 EPS for the current year.

Institutional Trading of Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC bought a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.